Tenax Therapeutics Expands Phase 3 LEVEL Program, Advancing Two TNX-103 (Oral Levosimendan) Registrational Studies for the Treatment of PH-HFpEF
Portfolio Pulse from
Tenax Therapeutics is expanding its Phase 3 LEVEL program for TNX-103 (Oral Levosimendan) to treat PH-HFpEF. The FDA has accepted an amendment to enlarge the study, increasing its statistical power, with full enrollment expected by the end of 2025.
March 05, 2025 | 2:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Tenax Therapeutics is expanding its Phase 3 LEVEL program for TNX-103, with FDA approval to enlarge the study, enhancing its statistical power. Full enrollment is expected by the end of 2025.
The expansion of the Phase 3 LEVEL program and FDA approval are positive developments for Tenax Therapeutics, potentially increasing the likelihood of successful trial outcomes. This could lead to future product approval and market opportunities, positively impacting the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100